As regulatory pathways for biosimilars evolve, traditional barriers to adoption may become less effective. Writing in a new PM360 Think Tank article, ICON’s Head of Centre for Biosimilar Drug Development considers how f...
ICON launches FIRECREST AI-directed video engine, changing the economics of site communications
Read the press releaseICON releases 2025 ICON Cares Report
Highlights progress in patient impact, innovation and sustainability
Read the press release